Vertex Pharmaceuticals Inc. has described polycystin-1 (PKD1) (mutant) correctors reported to be useful for the treatment of autosomal dominant polycystic kidney disease.
Astrazeneca AB has divulged 17β-hydroxysteroid dehydrogenase 13 (HSD17B13; 17β-HSD13) inhibitors reported to be useful for the treatment of alcoholic liver disease, liver fibrosis, cirrhosis, hepatic steatosis, liver inflammation, hepatitis C virus (HCV) infection and liver cancer (hepatocellular carcinoma).
Merck Sharp & Dohme LLC has identified compounds acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1 (HCN1) and/or 2 (HCN2) blockers reported to be useful for the treatment of neuropathic pain, tinnitus, psychiatric and neurological disorders.
Gilead Sciences Inc. has synthesized indoline compounds acting as DNA helicase-primase complex (human herpes simplex virus) and viral replication inhibitors reported to be useful for the treatment of herpes virus infection.
Biogen Inc. has disclosed non-receptor tyrosine-protein kinase TYK2 inhibitors reported to be useful for the treatment of stroke, psoriasis, arthritis, pain, silicosis, alopecia and more.
Kumquat Biosciences Inc. has described compounds acting as GTPase KRAS wild-type and mutant inhibitors reported to be useful for the treatment of cancer.
Evotec International GmbH has divulged NLRP3 inflammasome inhibitors reported to be useful for the treatment of asthma, cryopyrin-associated periodic syndromes, hypertension, Alzheimer’s disease, rheumatoid arthritis, diabetes, multiple sclerosis and Parkinson’s disease.
Beijing Tide Pharmaceutical Co. Ltd. has identified protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer and myelofibrosis.
RSS